MTHFR Polymorphisms Do Not Cause Macrocytosis
Common MTHFR polymorphisms (C677T and A1298C) are not a cause of macrocytosis and should not be routinely tested in the evaluation of macrocytic anemia. The most recent ACMG technical standard explicitly states that MTHFR variant testing is not recommended for thrombophilia or routine clinical evaluation 1.
Understanding the Relationship
While MTHFR is involved in folate metabolism, the common polymorphisms do not directly cause macrocytosis:
- MTHFR C677T polymorphism reduces enzyme activity but does not cause macrocytosis in the absence of actual folate or B12 deficiency 2, 1
- The polymorphism may contribute to elevated homocysteine levels, but homocysteine elevation itself does not cause macrocytosis 3
- Even in HIV patients receiving zidovudine (a known cause of macrocytic anemia), MTHFR C677T polymorphism was not a risk factor for developing macrocytosis 4
Severe MTHFR deficiency (homozygous pathogenic mutations causing enzyme deficiency) is an entirely different entity from common polymorphisms. This rare condition presents with severe neurological symptoms, hyperhomocysteinemia, and low methionine—not isolated macrocytosis 5, 6, 7.
Appropriate Work-Up for Macrocytosis
When evaluating macrocytosis (MCV >100 fL), follow this algorithmic approach 8:
Initial Laboratory Assessment:
- Reticulocyte count/index to distinguish production vs. destruction
- Vitamin B12 level (<200 pg/mL suggests deficiency)
- Folate level (serum or RBC folate)
- Methylmalonic acid (MMA) if B12 is borderline (>24.8 ng/mL indicates B12 deficiency) 9, 10
- Homocysteine level (elevated in both B12 and folate deficiency) 10
- Peripheral blood smear for megaloblastic changes
- TSH for hypothyroidism
- Liver function tests for alcohol-related causes
- Medication review (hydroxyurea, diphenytoin, methotrexate, zidovudine)
Do NOT Order:
- MTHFR genetic testing - it has no clinical utility for macrocytosis evaluation 1
Treatment Approach
For megaloblastic macrocytosis with confirmed B12 or folate deficiency 8:
Vitamin B12 Deficiency:
- Parenteral hydroxocobalamin 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly maintenance
- Oral B12 (1000-2000 mcg daily) is an alternative for non-severe cases without neurological symptoms
Folate Deficiency:
- Folic acid 1-5 mg daily orally
- Critical caveat: Always correct B12 deficiency first or simultaneously, as treating isolated folate deficiency can precipitate or worsen B12-related neurological damage 11, 10
If MTHFR 677TT Genotype is Incidentally Known:
- If homocysteine is elevated (>15 μmol/L), consider 5-methyltetrahydrofolate (5-MTHF) instead of folic acid, as it bypasses the MTHFR enzyme 12
- Standard dose: 400-800 mcg daily
- However, this is only relevant if there is documented hyperhomocysteinemia, not for macrocytosis itself
Common Pitfalls to Avoid
Do not attribute macrocytosis to MTHFR polymorphisms - this leads to missed diagnoses of true B12/folate deficiency, alcoholism, MDS, or medication effects
Do not order MTHFR testing as part of macrocytosis work-up - multiple professional societies (ACMG, ACOG, British Committee for Standards in Haematology) explicitly recommend against this 1
Do not treat with folate alone without checking B12 status - this can mask megaloblastic anemia while allowing irreversible neurological damage to progress 11
Do not confuse severe MTHFR deficiency with common polymorphisms - severe deficiency is a rare metabolic disorder presenting in infancy/childhood with neurological crisis, not adult-onset isolated macrocytosis 5, 6, 7
Recognize that elevated homocysteine requires evaluation for B12/folate deficiency and renal function, but the presence of MTHFR polymorphisms does not change management 3